Department of Pharmaceutics, SVKM'S B.N. College of Pharmacy, Mumbai, India.
AAPS PharmSciTech. 2012 Dec;13(4):1331-40. doi: 10.1208/s12249-012-9860-x. Epub 2012 Sep 28.
Telmisartan is an orally active nonpeptide angiotensin II receptor antagonist used in the management of hypertension. It is a Biopharmaceutics Classification System class II drug having aqueous solubility of 9.9 μg/ml. Telmisartan (TEL) nanocrystals were prepared by evaporative antisolvent precipitation technique using different stabilizers as PVPK30, TPGS, Poloxamer 188, and PEG 6000 in combination or singly. The nanosuspensions were characterized in terms of particle size distribution, zeta potential, and polydispersity index. The suspension containing PVPK30 and TPGS (1:1) showed least average particle size of 82.63 nm and polydispersity index of 0.472. The zeta potential of nanosuspensions ranged between 6.54 and 10.8 mV. An increase of 116.45% was evident in the specific surface area of the freeze-dried product. Contact angle of nanoparticles was also lowered to 27° as compared to 50.8° for TEL. Saturation solubility studies in various media revealed a significant increase in comparison to plain drug. An increase of 3.74× in saturation solubility in FaSSIF and 5.02× in FeSSIF was seen. In vitro dissolution profile of nanosuspension coated on pellets revealed release of 85% in water, 95% in 0.1 N HCl, and 75% in phosphate buffer in 30 min. Nanosuspensions were found to be stable in the presence of univalent and bivalent electrolytes. A tenfold increase in bioavailability was evident. Nanoparticles of telmisartan prepared by bottom-up technique proved to be effective in improving the oral bioavailability as a result of enhanced solubility and dissolution rate.
替米沙坦是一种口服活性的非肽类血管紧张素 II 受体拮抗剂,用于治疗高血压。它是一种生物药剂学分类系统 II 类药物,水溶解度为 9.9μg/ml。替米沙坦(TEL)纳米晶体通过蒸发抗溶剂沉淀技术制备,使用不同的稳定剂如 PVPK30、TPGS、泊洛沙姆 188 和 PEG 6000 组合或单独使用。纳米混悬液的特征在于粒径分布、Zeta 电位和多分散指数。含有 PVPK30 和 TPGS(1:1)的混悬液表现出最小的平均粒径为 82.63nm 和多分散指数为 0.472。纳米混悬液的 Zeta 电位在 6.54 到 10.8mV 之间。冻干产物的比表面积明显增加了 116.45%。纳米颗粒的接触角也从 TEL 的 50.8°降低到 27°。在各种介质中的饱和溶解度研究显示出与原药相比有显著增加。在 FaSSIF 中的饱和溶解度增加了 3.74 倍,在 FeSSIF 中增加了 5.02 倍。包衣在丸剂上的纳米混悬液的体外释放曲线显示,在水中释放 85%,在 0.1N HCl 中释放 95%,在磷酸盐缓冲液中 30 分钟内释放 75%。纳米混悬液在一价和二价电解质存在下是稳定的。生物利用度增加了 10 倍。通过自下而上的技术制备的替米沙坦纳米颗粒由于溶解度和溶解速率的提高,被证明能有效提高口服生物利用度。